Second-trimester ultrasound to detect fetuses with Down syndrome: A meta-analysis

JAMA

Volumn 285, Issue 8, 2001, Pages 1044-1055

  Smith Bindman, Rebecca ^a   Hosmer, Wylie ^a   Feldstein, Vickie A ^a   Deeks, Jonathan J ^b   Goldberg, James D ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOWN SYNDROME; FETUS; FETUS ECHOGRAPHY; FETUS MALFORMATION; HUMAN; MEDICAL INFORMATION; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY;

EID: 0035961570     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.285.8.1044     Document Type: Article

References (107)

1. Down's syndrome: Recent trends in the United States
2. Chromosomal abnormality rates at amniocentesis and in live-born infants
3. Biochemical and ultrasound screening for chromosomal abnormalities
4. Estimates of the economic costs of birth defects
5. Prematurity, birth defects, and early death: Impact on the family
6. Down syndrome in live births by single year maternal age interval in a Swedish study
7. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome
8. Maternal serum screening for Down's syndrome in early pregnancy
9. Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome
10. Maternal serum screening for fetal Down syndrome in the United States: A 1992 survey
11. Prenatal screening for Down's syndrome with use of maternal serum markers
12. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A
13. Randomised trial to assess safety and fetal outcome of early and midtrimester amniocentesis
14. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women
15. Invasive antenatal procedures and requirement for neonatal intensive care unit admission
16. The effects of mid-trimester amniocentesis on lung function in the neonatal period
17. Midtrimester amniocentesis for prenatal diagnosis: Safety and accuracy
18. An assessment of the hazards of amniocentesis: Report to the Medical Research Council by their Working Party on Amniocentesis
19. Ultrasoundally detectable markers of fetal chromosomal defects
20. Prenatal sonographic findings of Down syndrome: Review of 94 cases
21. Evaluation of prenatal diagnosis of congenital heart disease
22. Structural cardiac abnormalities in the fetus
23. Karyotype abnormalities in fetuses diagnosed as abnormal on ultrasound before 20 weeks' gestational age
24. The current role of sonography in the detection of Down syndrome
25. Ultrasound detection of Down syndrome
26. Chromosomal abnormalities detected after an abnormal ultrasound in pregnancy
27. Ultrasound screening for fetal abnormalities
28. Incidence of chromosomal abnormalities in 153 pregnancies with ultrasound detected fetal abnormalities
29. Ultrasound detection of genetic anomalies
30. Chromosomal abnormalities: How much can we predict by ultrasound examination in low-risk pregnancies?
31. Effectiveness of routine ultrasound in detecting fetal structural abnormalities in a low risk population
32. A randomized trial of prenatal ultrasound screening
33. End-result of routine ultrasound screening for congenital anomalies
34. Value of routine ultrasound scanning at 19 weeks
35. Routine radiographer screening for fetal abnormalities by ultrasound in an unselected low risk population
36. Can sonographers reliably identify anatomic features associated with Down syndrome in fetuses?
37. The second-trimester fetus with Down syndrome
38. Age-adjusted ultrasound risk assessment for fetal Down's syndrome during the second trimester
39. Sonographic identification of second-trimester fetuses with Down's syndrome
40. Echogenic intracardiac focus
41. A sonographic screening method for Down syndrome
42. Femur length shortening in the detection of Down syndrome
43. Second-trimester ultrasound markers for detection of trisomy 21
44. Can the presumed risk of autosomal trisomy be decreased in fetuses of older women following a normal sonogram?
45. The "genetic sonogram": Comparison of the index scoring system with the age-adjusted US risk assessment
46. Adjusting the risk for trisomy 21 on the basis of second-trimester ultrasound
47. Antenatal screening for Down's syndrome
48. Obstetrical sonography: The best way to terrify a pregnant woman
49. Meta-analytic methods for diagnostic test accuracy
50. Systematic reviews of evaluations of diagnostic and screening tests
51. Meta-analysis in clinical trials
52. Normal nuchal thickness in the midtrimester indicates reduced risk of Down syndrome in pregnancies with abnormal triple-screen results
53. Ultrasoundally adjusted midtrimester risk of trisomy 21 and significant chromosomal defects in advanced maternal age
54. A sonographic sign for the detection in the second trimester of the fetus with Down's syndrome
55. Down syndrome: Sonographic sign for diagnosis in the second-trimester fetus
56. Humeral shortening in second-trimester fetuses with Down syndrome
57. Sonographic scoring index for prenatal detection of chromosomal abnormalities
58. Identification of second-trimester fetuses with autosomal trisomy by use of a sonographic scoring index
59. Humerus and femur length in fetuses with Down syndrome
60. Criteria for fetal nuchal thickness cut-off
61. 6-Year experience of prenatal diagnosis in an unselected population in Oxford, UK
62. The incorporation of maternal age into the sonographic scoring index for the detection at 14-20 weeks of fetuses with Down's syndrome
63. Sonographic measurements and ratios in fetuses with Down syndrome
64. Efficacy of the biparietal diameter/femur length ratio to detect Down syndrome in patients with an abnormal biochemical screen
65. A sonographic and karyotypic study of second-trimester fetal choroid plexus cysts
66. Sonographically measured nuchal skinfold thickness as a screening tool for Down syndrome
67. Ultrasound retal femur length measurement in the screening for Down's syndrome
68. Subtle ultrasound anomalies
69. The use of color Doppler ultrasound to identify fetuses at increased risk for trisomy 21
70. Fetal biometry as a screening tool for the detection of chromosomally abnormal pregnancies
71. Prospective multicenter study of second-trimester nuchal skinfold thickness in unaffected and Down syndrome pregnancies
72. Screening for fetal anomalies by ultrasound at 14 and 21 weeks
73. Second-trimester minor ultrasound anomalies
74. Ultrasound detection of the second-trimester fetus with trisomy 18 and trisomy 21
75. Femur/foot length ratio for detection of Down syndrome
76. Sonographic measurement of nuchal skinfoid thickness for detection of Down syndrome in the second-trimester fetus
77. Is genetic amniocentesis warranted when isolated choroid plexus cysts are found?
78. Optimal nuchal skin-fold thresholds based on gestational age for prenatal detection of Down syndrome
79. Femur length in the US prediction of trisomy 21 and other chromosomal abnormalities
80. Fetal leg and femur/foot length ratio: A marker for trisomy 21
81. Combining humerus and femur length for improved ultrasound identification of pregnancies at increased risk for trisomy 21
82. Fetal femur length to detect trisomy 21
83. The effect of fetal gender on the prediction of Down syndrome by means of maternal serum alpha-fetoprotein and ultrasound parameters
84. Significance of fetal intracardiac echogenic loci in relation to trisomy 21
85. Screening for trisomy 21 with ultrasound determination of biparietal diameter/femur length ratio
86. Ultrasoundally detectable markers of fetal chromosomal abnormalities
87. Humerus and femur length shortening in the detection of Down's syndrome
88. Role of prenatal ultrasound in women with positive screen for Down syndrome on the basis of maternal serum markers
89. Comparison of humerus length with femur length in fetuses with Down syndrome
90. Biparietal diameter/femur length ratio, cephalic index, and femur length measurements
91. The role of ultrasound markers for trisomy 21 in women with positive serum biochemistry
92. Best second trimester sonographic markers for the detection of trisomy 21
93. Prevalence of aneuploidy with a cardiac intraventricular echogenic focus in an at-risk patient population
94. Adjusting the risk for trisomy 21 by a simple ultrasound method using fetal long-bone biometry
95. Ultrasound measurement of fetal nuchal skin to screen for chromosomal abnormalities
96. Isolated fetal pyelectasis
97. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities
98. Users' guides to the medical literature, III: How to use an article about a diagnostic test
99. Preferences of women facing a prenatal diagnostic choice
100. Women's decision-making in prenatal screening
101. Towards informed decisions about prenatal testing
102. Parental reaction and adaptability to the prenatal diagnosis of fetal defect or genetic disease leading to pregnancy interruption
103. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters
104. Monitoring trends in prenatal diagnosis of Down's syndrome in England and Wales, 1989-92
105. Empirical evidence of design-related bias in studies of diagnostic tests